Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with more on the serious and lifelong nature of celiac disease to mark Celiac Awareness Month.
Contrary to common misconceptions about gluten intolerance, where dietary changes alone are often deemed sufficient, Vitt emphasized that such adjustments do not adequately manage celiac disease symptoms, which are persistent and require more significant intervention.
Currently, Immunic is developing a new treatment option, IMU-856, specifically targeting celiac disease. This program marks an important step in the clinical development journey, as the company recently shared with the first clinical proof of concept data for the treatment.
Vitt affirmed the company's commitment to advancing treatment options for those affected by celiac disease.